The influence of smoking on bone loss and response to nasal estradiol

N.H. Bjarnason; T.F. Nielsen; Henrik Løvendahl Jørgensen; C. Christiansen

The influence of smoking on bone loss and response to nasal estradiol

N.H. Bjarnason, T.F. Nielsen, Henrik Løvendahl Jørgensen, C. Christiansen

11 Citations (Scopus)

Abstract

Objective To investigate the influence of smoking on bone during therapy with nasally administrated estradiol in sequential combination with oral progesterone in early postmenopausal women. In addition, to observe the consequences of smoking on bone in untreated women. Methods Post-hoc exploratory analyses of data from 270 postmenopausal women randomized to 2 years' therapy with daily nasal administration of 17-estradiol or placebo sequentially combined with oral micronized progesterone in the active groups or placebo in the placebo group. Results During treatment with nasal estradiol, the bone mineral density (BMD) of the lumbar spine had increased less at 2 years in smokers as compared to non-smokers (2.6% vs. 3.9%, p=0.03). Parallel changes were seen in the placebo group (-3.6% vs. -2.4%, p=0.08). In the total hip BMD, there was no difference in the response to estradiol in smokers vs. non-smokers (1.4% vs. 1.4%, p=0.89), whereas the change in the hip on the placebo was similar to that seen in the spine (-3.7% vs. -2.6%, p=0.08). Supportive changes were seen in urinary CTX and in serum osteocalcin. Conclusions These results indicate that cigarette smoking may reduce the efficacy of nasal estradiol to increase bone mass in early postmenopausal women. In addition, smoking may increase spontaneous bone loss in untreated women
Udgivelsesdato: 2009

Original language	English
Journal	Climacteric
Volume	12
Issue number	1
Pages (from-to)	59-65
Number of pages	6
ISSN	1369-7137
Publication status	Published - 2009

Cite this

@article{91379ee0899811df928f000ea68e967b,

title = "The influence of smoking on bone loss and response to nasal estradiol",

abstract = "Objective To investigate the influence of smoking on bone during therapy with nasally administrated estradiol in sequential combination with oral progesterone in early postmenopausal women. In addition, to observe the consequences of smoking on bone in untreated women. Methods Post-hoc exploratory analyses of data from 270 postmenopausal women randomized to 2 years' therapy with daily nasal administration of 17-estradiol or placebo sequentially combined with oral micronized progesterone in the active groups or placebo in the placebo group. Results During treatment with nasal estradiol, the bone mineral density (BMD) of the lumbar spine had increased less at 2 years in smokers as compared to non-smokers (2.6% vs. 3.9%, p=0.03). Parallel changes were seen in the placebo group (-3.6% vs. -2.4%, p=0.08). In the total hip BMD, there was no difference in the response to estradiol in smokers vs. non-smokers (1.4% vs. 1.4%, p=0.89), whereas the change in the hip on the placebo was similar to that seen in the spine (-3.7% vs. -2.6%, p=0.08). Supportive changes were seen in urinary CTX and in serum osteocalcin. Conclusions These results indicate that cigarette smoking may reduce the efficacy of nasal estradiol to increase bone mass in early postmenopausal women. In addition, smoking may increase spontaneous bone loss in untreated women Udgivelsesdato: 2009",

author = "N.H. Bjarnason and T.F. Nielsen and J{\o}rgensen, {Henrik L{\o}vendahl} and C. Christiansen",

note = "Times Cited: 1ArticleEnglishBjarnason, N. HCtr Clin & Basic Res, Ballerup Byvej 222, DK-2750 Ballerup, DenmarkCited References Count: 31389PQTAYLOR & FRANCIS LTD4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDABINGDON",

year = "2009",

language = "English",

volume = "12",

pages = "59--65",

journal = "Climacteric",

issn = "1369-7137",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - The influence of smoking on bone loss and response to nasal estradiol

AU - Bjarnason, N.H.

AU - Nielsen, T.F.

AU - Jørgensen, Henrik Løvendahl

AU - Christiansen, C.

N1 - Times Cited: 1ArticleEnglishBjarnason, N. HCtr Clin & Basic Res, Ballerup Byvej 222, DK-2750 Ballerup, DenmarkCited References Count: 31389PQTAYLOR & FRANCIS LTD4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDABINGDON

PY - 2009

Y1 - 2009

N2 - Objective To investigate the influence of smoking on bone during therapy with nasally administrated estradiol in sequential combination with oral progesterone in early postmenopausal women. In addition, to observe the consequences of smoking on bone in untreated women. Methods Post-hoc exploratory analyses of data from 270 postmenopausal women randomized to 2 years' therapy with daily nasal administration of 17-estradiol or placebo sequentially combined with oral micronized progesterone in the active groups or placebo in the placebo group. Results During treatment with nasal estradiol, the bone mineral density (BMD) of the lumbar spine had increased less at 2 years in smokers as compared to non-smokers (2.6% vs. 3.9%, p=0.03). Parallel changes were seen in the placebo group (-3.6% vs. -2.4%, p=0.08). In the total hip BMD, there was no difference in the response to estradiol in smokers vs. non-smokers (1.4% vs. 1.4%, p=0.89), whereas the change in the hip on the placebo was similar to that seen in the spine (-3.7% vs. -2.6%, p=0.08). Supportive changes were seen in urinary CTX and in serum osteocalcin. Conclusions These results indicate that cigarette smoking may reduce the efficacy of nasal estradiol to increase bone mass in early postmenopausal women. In addition, smoking may increase spontaneous bone loss in untreated women Udgivelsesdato: 2009

AB - Objective To investigate the influence of smoking on bone during therapy with nasally administrated estradiol in sequential combination with oral progesterone in early postmenopausal women. In addition, to observe the consequences of smoking on bone in untreated women. Methods Post-hoc exploratory analyses of data from 270 postmenopausal women randomized to 2 years' therapy with daily nasal administration of 17-estradiol or placebo sequentially combined with oral micronized progesterone in the active groups or placebo in the placebo group. Results During treatment with nasal estradiol, the bone mineral density (BMD) of the lumbar spine had increased less at 2 years in smokers as compared to non-smokers (2.6% vs. 3.9%, p=0.03). Parallel changes were seen in the placebo group (-3.6% vs. -2.4%, p=0.08). In the total hip BMD, there was no difference in the response to estradiol in smokers vs. non-smokers (1.4% vs. 1.4%, p=0.89), whereas the change in the hip on the placebo was similar to that seen in the spine (-3.7% vs. -2.6%, p=0.08). Supportive changes were seen in urinary CTX and in serum osteocalcin. Conclusions These results indicate that cigarette smoking may reduce the efficacy of nasal estradiol to increase bone mass in early postmenopausal women. In addition, smoking may increase spontaneous bone loss in untreated women Udgivelsesdato: 2009

M3 - Journal article

SN - 1369-7137

VL - 12

SP - 59

EP - 65

JO - Climacteric

JF - Climacteric

IS - 1

ER -